CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Ritonavir +1 moredrug
Likely dose
Ritonavir 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00435929
NCT00435929Phase 1Completed

Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients

Hoffmann-La Roche·interventional·Posted Feb 16, 2007·Updated Mar 29, 2018

In Brief

A Phase 1 clinical trial evaluating Ritonavir and saquinavir [Invirase] for HIV Infections. Completed, enrolled 16 participants across 8 sites in 3 countries.

Detailed Summary

This 2 arm study will assess the effect of moderate liver impairment on the pharmacokinetics of saquinavir and ritonavir at steady state following administration of saquinavir/ritonavir 1000mg/100mg po bid in HIV patients. Saquinavir/ritonavir will be administered concomitantly with 2 to 3 active nucleoside reverse transcriptase inhibitors. The study will compare a group of HIV patients without known liver disease and a group with moderate liver disease. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesCanada, Puerto Rico, United States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 16, 2007
Enrollment StartSep 1, 2006
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 19.4 years ago

Interventions

Ritonavirdrug

100mg po bid

saquinavir [Invirase]drug

1000mg po bid